Breaking News, Trials & Filings

CureVac Expands Late-stage Trials of COVID Vax Candidate

Further analysis to determine efficacy of the vaccine candidate for new virus variants.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CureVac N.V. plans to expand and further specify the protocols of its ongoing late-stage clinical trials with its COVID-19 vaccine candidate, CVnCoV.   CVnCoV efficacy is currently being evaluated in the HERALD Phase 2b/3 trial in Europe and Latin America. New virus variants in the countries where the study is conducted supports the need for further analysis to determine efficacy of the vaccine candidate for select variants.   For its Phase 2a dose-confirmation trial in older adults in Peru ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters